NASDAQ:KIN Kindred Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kindred Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.29 +0.40 (+8.18 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$4.91Now: $5.29▼$5.2950-Day Range$3.29MA: $4.14▼$5.0852-Week Range$3.11Now: $5.29▼$11.93Volume406,264 shsAverage Volume313,301 shsMarket Capitalization$208.26 millionP/E RatioN/ADividend YieldN/ABeta1.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingKindred Biosciences has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Kindred Biosciences has a forecasted upside of 107.9% from its current price of $5.29.Amount of Analyst CoverageKindred Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesKindred Biosciences has received 363 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKindred Biosciences has received 343 “underperform” votes. (Add your “underperform” vote.)Community SentimentKindred Biosciences has received 51.42% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote “Outperform” if you believe KIN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKindred Biosciences does not currently pay a dividend.Dividend GrowthKindred Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kindred Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $542,291.00 in company stock.Percentage Held by InsidersOnly 12.63% of the stock of Kindred Biosciences is held by insiders.Percentage Held by Institutions67.06% of the stock of Kindred Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kindred Biosciences are expected to decrease in the coming year, from ($0.48) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kindred Biosciences is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kindred Biosciences is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKindred Biosciences has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KIN Previous Symbol CUSIPN/A CIK1561743 Webkindredbio.com Phone650-701-7901Debt Debt-to-Equity Ratio0.26 Current Ratio10.47 Quick Ratio10.42Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.26 million Price / Sales48.89 Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book2.52Profitability EPS (Most Recent Fiscal Year)($1.59) Net Income$-61,390,000.00 Net Margins-69.69% Return on Equity-28.14% Return on Assets-20.39%Miscellaneous Employees146 Outstanding Shares39,368,000Market Cap$208.26 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $5.29 +0.40 (+8.18 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KIN News and Ratings via Email Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter. Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions How has Kindred Biosciences' stock been impacted by COVID-19 (Coronavirus)? Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KIN stock has decreased by 34.6% and is now trading at $5.29. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Kindred Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kindred Biosciences. When is Kindred Biosciences' next earnings date? Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Kindred Biosciences. How were Kindred Biosciences' earnings last quarter? Kindred Biosciences Inc (NASDAQ:KIN) released its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $0.65 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.00 by $0.65. The biopharmaceutical company earned $39.57 million during the quarter, compared to analysts' expectations of $19.77 million. Kindred Biosciences had a negative net margin of 69.69% and a negative return on equity of 28.14%. View Kindred Biosciences' earnings history. What price target have analysts set for KIN? 5 brokers have issued 12 month price objectives for Kindred Biosciences' stock. Their forecasts range from $9.00 to $13.00. On average, they expect Kindred Biosciences' stock price to reach $11.00 in the next year. This suggests a possible upside of 107.9% from the stock's current price. View analysts' price targets for Kindred Biosciences. Are investors shorting Kindred Biosciences? Kindred Biosciences saw a drop in short interest during the month of August. As of August 14th, there was short interest totaling 593,400 shares, a drop of 14.9% from the July 30th total of 696,900 shares. Based on an average daily volume of 400,700 shares, the short-interest ratio is presently 1.5 days. Approximately 1.6% of the shares of the company are short sold. View Kindred Biosciences' Short Interest. Who are some of Kindred Biosciences' key competitors? Some companies that are related to Kindred Biosciences include VBI Vaccines (VBIV), Protagonist Therapeutics (PTGX), resTORbio (TORC), Kadmon (KDMN), Endo International (ENDP), Phibro Animal Health (PAHC), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), ImmunoGen (IMGN), Collegium Pharmaceutical (COLL), DiaMedica Therapeutics (DMCAF), Cara Therapeutics (CARA), Omeros (OMER), Northwest Biotherapeutics (NWBO) and Emisphere Technologies (EMIS). View all competitors. What other stocks do shareholders of Kindred Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Novavax (NVAX), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Canopy Growth (CGC), InVitae (NVTA), Opko Health (OPK) and Rigel Pharmaceuticals (RIGL). Who are Kindred Biosciences' key executives? Kindred Biosciences' management team includes the following people: Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)Ms. Wendy K. Wee, Chief Financial Officer (Age 66)Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations What is Kindred Biosciences' stock symbol? Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN." Who are Kindred Biosciences' major shareholders? Kindred Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.38%), Nuveen Asset Management LLC (0.36%), UBS Group AG (0.33%), Goldman Sachs Group Inc. (0.27%), Charles Schwab Investment Management Inc. (0.26%) and Hound Partners LLC (0.20%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View institutional ownership trends for Kindred Biosciences. Which institutional investors are selling Kindred Biosciences stock? KIN stock was sold by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., and WINTON GROUP Ltd. View insider buying and selling activity for Kindred Biosciences. Which institutional investors are buying Kindred Biosciences stock? KIN stock was purchased by a variety of institutional investors in the last quarter, including Hound Partners LLC, Goldman Sachs Group Inc., Cim Investment Mangement Inc., Tudor Investment Corp Et Al, SG Americas Securities LLC, Bank of New York Mellon Corp, State of Wisconsin Investment Board, and Nuveen Asset Management LLC. View insider buying and selling activity for Kindred Biosciences. How do I buy shares of Kindred Biosciences? Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kindred Biosciences' stock price today? One share of KIN stock can currently be purchased for approximately $5.29. How big of a company is Kindred Biosciences? Kindred Biosciences has a market capitalization of $208.26 million and generates $4.26 million in revenue each year. The biopharmaceutical company earns $-61,390,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe. What is Kindred Biosciences' official website? The official website for Kindred Biosciences is kindredbio.com. How can I contact Kindred Biosciences? Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
